Bisphosphonates in breast cancer: Antitumor effects

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 4, 2011, Pages 292-299

  Aft, Rebecca ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Zoledronic acid

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CAPECITABINE; CLODRONIC ACID; DASATINIB; DENOSUMAB; DOCETAXEL; EPIRUBICIN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PACLITAXEL; PAMIDRONIC ACID; SARACATINIB; TAMOXIFEN; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RISK; COMBINATION CHEMOTHERAPY; CONSTIPATION; DISSEMINATED CANCER; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INJECTION SITE REACTION; JAW OSTEONECROSIS; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; SCLERITIS; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; TUMOR CELL; UVEITIS; VOMITING;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 79955736464     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8:1080-1084.
2. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893-2897.
3. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cyto-kines in metastatic breast cancer patients. Oncology. 2005;69:35-43.
4. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482-4486.
5. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-206.
6. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102:2310-2311.
7. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma-9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290-297.
8. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802.
9. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103:884-891.
10. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421-428.
11. Aft R, Trinkaus K, Weilbaecher K. Effect of zoledronic acid on disease free survival and overall survival in women with clinic stage II/III undergoing neoadjuvant chemotherapy for breast cancer. Poster presented at: the 2010 San Antonio Breast Cancer Symposium; December 12, 2010; San Antonio, Texas.
12. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Poster presented at: the 2007 San Antonio Breast Cancer Symposium; December 15, 2007; San Antonio, Texas.
13. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res. 2008;69(suppl 2):170s-171s. Abstract 2048.
14. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552-2559.
15. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007;12:1035-1043.
16. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96:1796-1801.
17. Coleman R. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Paper presented at: the 2010 San Antonio Breast Cancer Symposium; December 10, 2010; San Antonio, Texas.
18. De Boer RH, Bundred N, Eidtmann H, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Poster presented at: the 2010 San Antonio Breast Cancer Symposium; December 11, 2010; San Antonio, Texas.
19. Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine responsive breast cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 533.
20. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-691.
21. Gnant M, Mlineritsch B, Stoeger H, et al. The carry-over effect of adjuvant zoledronic acid: comparison of 48- and 62-month analyses of ABCSG-12 suggests that the benefits of combining zoledronic acid with adjuvant endocrine therapy persist long after completion of therapy. Poster presented at: the 2010 San Antonio Breast Cancer Symposium; December 11, 2010; San Antonio, Texas.
22. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer. 2010;102:1099-1105.
23. Coleman R, Bundred N, DeBoer RH, et al. Impact of zoledronic acid in post- menopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Poster presented at: the 2009 San Antonio Breast Cancer Symposium; December 12, 2009; San Antonio, Texas.
24. Kokufu I, Kohno N, Takao S. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;23: Abstract 530.
25. Jung J, Hwang G, Lee Y. Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:Abstract 888.
26. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582-3590.
27. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010;102:799-802.
28. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28:3577-3581.
29. Coghlin C, Murray GI. Current and emerging concepts in tumor metastases. J Pathol. 2010;222:1-15.
30. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335:1785-1791.
31. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98: 1735-1744.
32. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2011.
33. Aredia [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2008.
34. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:85-96.
35. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
36. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
37. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.
38. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27:Abstract 1011.
39. Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triplenegative breast cancer: results of study CA 180059. Poster presented at: the 2008 San Antonio Breast Cancer Symposium; December 12, 2008; San Antonio, Texas.
40. Morris PG, Abbruzzi A, D'Andrea G, et al. A phase I-II trial of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma. Poster presented at: the 2010 San Antonio Breast Cancer Symposium; December 12, 2010; San Antonio, Texas.
41. Cortes J, Specht J, Gradishar W, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase 1 CA 180-004. Poster presented at: the 2009 San Antonio Breast Cancer Symposium; December 11, 2009; San Antonio, Texas.
42. Pegram M, Silva O, Higgins C, et al. Src kinase inhibition with AZD0530 (saracatinib) plus anastrozole in postmenopausal hormone receptor positive (HR+) metastatic breast cancer. Poster presented at the 2010 San Antonio Breast Cancer Symposium; December 10, 2010; San Antonio, Texas.
43. Traina TA, Sparano JA, Caravelli J, et al. Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 1086.